DEB-TACE may be a therapeutic option for advanced HCC patients with PVI



Systemic therapies are regarded as a standard treatment for hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI)

Copyright © 2020 Terumo India Private limited

X
Important information regarding

By using this website, you consent to the use of cookies in accordance with our